The Preliminary Reprot Of Autologous Peripheral Blood Stem Cell Transplantation (Apbsct) For 18 Patients With Solid Tumors

Objective To study the feasibility and efficacy of high dose chemotherapy with the support of autologous peripheral blood stem cell (APBSC) for patients.Methods A total of 18 patients with solid tumors underwent APBSCT from February, 1999. Median age was 40 (12-76). 18 patients were pathologically confirmed: Multiple myeloma, 1 case; Non-hodgkin's lymphoma,7 cases; Small cell lung cancer,1 case;Ovary cancer, 2 cases; Breast cancer, 4 cases; and Soft tissue sarcoma, 3 cases. 18 patients obtained shrink or removal of lesion after conventional chemotherapy (CT) or surgical operation. The peripheral blood stem cell (PBSC) was mobilized by combination of chemotherapy and recombinant human granulocyte colony-stimulating factors (rhG-CSF). APBSC was harvested by CS-3000Plus Blood Cell Separator after mobilization. The enough number of mononuclear cell (MNC) and CD34+ cell was obtained by PBSC havesting in 1 or 2 times for each patients. The PBSCs of 14 patients were stored at 4, then the conditioning regimen was given and APBSCs were reinfused after 48 hours of CT . The PBSCs of 4 patients were frozen at-196. The patients lived in a highly efficient participate air filtered room until the reconstitution of the hematopoietic function. The patients left the laminarflow room when the leucocytes count ascended more than 1. 5 X 109/L. The patients were re-examined after 3 weeks, those with residual disease received radiotherapy.Results The overall respone rate was 100% (CR67% ,PR33%). Hematologic recovery was rapid. WBC count ascended beyond 1. 0X109/L on 10-12th day, the platelet count was beyond 50X109/L on 12-24th day. The major toxicities were myelosup-pression of IV grade, gastroenteric sidereaction,mucusitis of oral-cavity and infection of respiratory system. None of the patients was complicated with severe other complication, and there was no transplantation-related death. Median follow-up time was 6 month (from 3 month tolO month) 10 cases were still in disease-free survival (DPS), 5 cases were died of recurrence or matastasis, and 3 cases were in disease companing survival (DCS).Conclusion High dose chemotherapy with APBSC support for solid tumor was effective, secure, feasible. The speed of hematologic recovery is related to the number of MNC. Further studies on the chemorefactory recurrent patients are needed in the future.